肿瘤基础病危重患儿的出血流行病学
该回顾性队列研究纳入2018年某综合癌症中心PICU收治的28天至18岁、有肿瘤基础病的患儿267例次,采用新制定的危重患儿出血评估量表定义严重出血。9%(23/267)在PICU期间发生至少一次严重出血;出血组与非出血组在性别(p=0.07)、年龄(p=0.66)、体重(p=0.76)、移植状态(p=0.18)上无显著差异,但不同肿瘤诊断间严重出血频率有差异(p=0.009)。出血当天中位血小板102×10⁹/L(40-181×10⁹/L)、INR 1.36(1.26-1.51);87%(20/23)接受至少一种血制品,仅2例接受抗纤溶药。严重出血组无PICU天数更少(p=0.001)、无呼吸机天数更少(p<0.001)、28天死亡率更高(p=0.003)。作者认为需研究指导该人群严重出血的治疗。
要点
- 肿瘤基础病危重患儿中9%(23/267)发生至少一次严重出血,出血当天中位血小板102×10⁹/L(40-181×10⁹/L)、INR 1.36(1.26-1.51),多无严重血小板减少或凝血病。
- 严重出血组与非出血组在性别(p=0.07)、年龄(p=0.66)、体重(p=0.76)、移植状态(p=0.18)上无显著差异,但不同肿瘤诊断间出血频率有差异(p=0.009)。
- 严重出血患者87%(20/23)接受至少一种血制品,仅2例接受抗纤溶药。
- 严重出血组无PICU天数更少(p=0.001)、无呼吸机天数更少(p<0.001)、28天死亡率更高(p=0.003)。
适用人群与场景
- 28天至18岁、有肿瘤基础病、2018年收住综合癌症中心PICU的患儿,共267例次入院。
诊断标准与关键阈值
- 采用新制定的危重患儿出血评估量表(Bleeding Assessment Scale in Critically Ill Children)定义严重出血事件。
处置流程与药物剂量
- 严重出血患者中87%(20/23)接受至少一种血制品治疗以应对出血;2例接受抗纤溶药。
研究设计与关键结果
- 回顾性队列研究,纳入267例次PICU入院,64%(171/267)为男性,中位年龄6.3岁(3.1-12.1岁)。
- 9%(23/267)在PICU期间发生至少一次严重出血。
- 出血组与非出血组性别(p=0.07)、年龄(p=0.66)、体重(p=0.76)、移植状态(p=0.18)无显著差异;不同肿瘤诊断间严重出血频率有差异(p=0.009)。
- 严重出血患者出血当天中位血小板102×10⁹/L(40-181×10⁹/L)、INR 1.36(1.26-1.51)。
- 87%(20/23)严重出血患者接受至少一种血制品;2例接受抗纤溶药。
- 严重出血组无PICU天数更少(p=0.001)、无呼吸机天数更少(p<0.001)、28天死亡率更高(p=0.003)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该人群严重出血多发生在无严重血小板减少或凝血病时,绝大多数接受血制品治疗而很少使用止血药物;需研究指导这一脆弱人群严重出血的治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Critically ill children with malignancy have significant risk of bleeding but the exact epidemiology is unknown. We sought to describe severe bleeding events and associated risk factors in critically ill pediatric patients with an underlying oncologic diagnosis using the newly developed Bleeding Assessment Scale in Critically Ill Children definition.
DESIGN: Retrospective cohort study.
SETTING: PICU in comprehensive cancer center.
PATIENTS: Children ages 28 days to 18 years with an underlying oncologic diagnosis admitted to the PICU during 2018.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Two-hundred sixty-seven admissions met inclusion criteria. Sixty-four percent (171/267) were male, with a median (interquartile range) age of 6.3 years (3.1-12.1 yr). Nine percent (23/267) had at least one severe bleeding event during their PICU admission. There were no significant differences between those with severe bleeding and those without, with respect to gender (p = 0.07), age (p = 0.66), weight (p = 0.76), or transplant status (p = 0.18). There was a difference in the frequency of severe bleeding based on underlying oncologic diagnosis (p = 0.009). For patients with severe bleeding, the median (interquartile range) platelet count and international normalized ratio on the day of bleeding were 102 × 109/L (40-181 × 109/L) and 1.36 (1.26-1.51), respectively. Eighty-seven percent patients (20/23) with severe bleeding received at least one blood component in response to bleeding. Two patients received antifibrinolytics. Patients with severe bleeding had significantly fewer PICU-free days (p = 0.001), fewer ventilator-free days (p < 0.001), and higher 28-day mortality (p = 0.003).
CONCLUSIONS: Severe bleeding occurred in nearly one-tenth of critically ill children with an underlying oncologic diagnosis without severe thrombocytopenia or coagulopathy. The vast majority received blood component therapy, but few received hemostatic medication. Studies are needed to guide the treatment of severe bleeding in this vulnerable patient population.
参考来源
- Romano J, Martinez M, Levasseur J, et al. Epidemiology of Bleeding in Critically Ill Children With an Underlying Oncologic Diagnosis. Crit Care Explor. 2021. PMID: 34746797. doi:10.1097/CCE.0000000000000572
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。